Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
2.
Heliyon ; 8(4): e09317, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35520616

ABSTRACT

The next generation of wireless communication networks will rely heavily on machine learning and deep learning. In comparison to traditional ground-based systems, the development of various communication-based applications is projected to increase coverage and spectrum efficiency. Machine learning and deep learning can be used to optimize solutions in a variety of applications, including antennas. The latter have grown popular for obtaining effective solutions due to high computational processing, clean data, and large data storage capability. In this research, machine learning and deep learning for various antenna design applications have been discussed in detail. The general concept of machine learning and deep learning is introduced. However, the main focus is on various antenna applications, such as millimeter wave, body-centric, terahertz, satellite, unmanned aerial vehicle, global positioning system, and textiles. The feasibility of antenna applications with respect to conventional methods, acceleration of the antenna design process, reduced number of simulations, and better computational feasibility features are highlighted. Overall, machine learning and deep learning provide satisfactory results for antenna design.

3.
Indian J Crit Care Med ; 25(4): 416-420, 2021 Apr.
Article in English | MEDLINE | ID: mdl-34045809

ABSTRACT

INTRODUCTION: The main purpose of this study was to evaluate the effectiveness of graded early mobilization on psychomotor status and duration of ICU stay of patients with mechanical ventilation. MATERIALS AND METHODS: Design: Quasi-experimental study.Setting: BRB Hospitals Limited, Dhaka, Bangladesh. A reputed 500-beddedgeneral hospital with 30 ICU beds.Participants: A total of 30 patients were selected as participants in the study from the hospital. 15 patients were included in the ICU treatment group and the remaining 15 were in the intervention group using the purposive sampling method.Scales used: Functional independence measure (FIM) scale and 7 point generalized anxiety depression (GAD-7) scale.Intervention: Graded early mobilization was provided as an intervention to all participants of the intervention group by a professionally qualified ICU physiotherapist for 10 sessions. Most of the patients received multiple sessions of intervention within a day. RESULTS: In the control group mean FIM score was 17.40 (SD±4.88), and in the intervention group mean score was 65.70 (SD±12.18). The mean difference was statistically significant in the 't' test (p-value > 0.001). In the control group, the mean GAD-7 score was 19.50 (SD±2.71), and in the intervention group the mean GAD-7 score was 7.5 (SD±2.59). The mean difference was statistically significant in the 't' test. (p-value > 0.001). The mean length of ICU stay in the control group was 5.60 (SD±1.07) and in the intervention group it was 3.10 (SD±0.56). The mean difference was statistically significant in the 't' test (p-value > 0.001). CONCLUSION: This research showed that graded early mobilization was highly effective to improve the motor and psychological status of mechanically ventilated patients and reduce their length of ICU stay. HOW TO CITE THIS ARTICLE: Das B, Saha S, Kabir F, Hossain S. Effect of Graded Early Mobilization on Psychomotor Status and Length of Intensive Care Unit Stay in Mechanically Ventilated Patients. Indian J Crit Care Med 2021;25(4):416-420.

4.
Drug Deliv Transl Res ; 8(3): 484-495, 2018 06.
Article in English | MEDLINE | ID: mdl-29508159

ABSTRACT

Most medications targeting optic neuropathies are administered as eye drops. However, their corneal penetration efficiencies are typically < 5%. There is a clear, unmet need for novel transcorneal drug delivery vehicles. To this end, we have developed a stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for controlled release of poorly bioavailable drugs into the aqueous humor of the eye. The hydrogel is formulated as a composite of hyaluronic acid (HA) and methylcellulose (MC). The amphiphilic nanoparticles are composed of poly(ethylene oxide) (PEO) and poly(lactic acid) (PLA). Experimental design aided the identification of hydrogel composition and nanoparticle content in the formulation, and the formulation reliably switched between thixotropy and temperature-dependent rheopexy when it was tested in a rheometer under conditions that simulate the ocular surface, including blinking. These properties should ensure that the formulation coats the cornea through blinking of the eyelid and facilitate application of the medication as an eye drop immediately prior to the patient's bedtime. We subsequently tested the efficacy of our formulation in whole-eye experiments by loading the nanoparticles with cannabigerolic acid (CBGA). Our formulation exhibits over a 300% increase in transcorneal penetration over control formulations. This work paves the way for the introduction of novel products targeting ocular diseases to the market.


Subject(s)
Benzoates/administration & dosage , Cornea/metabolism , Hydrogels/administration & dosage , Nanoparticles/administration & dosage , Administration, Ophthalmic , Animals , Benzoates/metabolism , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/chemistry , Drug Compounding , Escherichia coli/genetics , Escherichia coli/metabolism , Hyaluronic Acid/administration & dosage , Hyaluronic Acid/chemistry , Hydrogels/chemistry , Methylcellulose/administration & dosage , Methylcellulose/chemistry , Nanoparticles/chemistry , Polyesters/administration & dosage , Polyesters/chemistry , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/chemistry , Rheology , Swine
5.
Curr Cancer Drug Targets ; 17(8): 707-721, 2017.
Article in English | MEDLINE | ID: mdl-28359244

ABSTRACT

BACKGROUND: Mutations in proto-oncogenes and tumor suppressor genes make cancer cells proliferate indefinitely. As they possess almost all mechanisms for cell proliferation and survival like healthy cells, it is difficult to specifically target cancer cells in the body. Current treatments in most of the cases are harmful to healthy cells as well. Thus, it would be of great prudence to target specific characters of cancer cells. Since cancer cells avidly use glucose and glutamine to survive and proliferate by upregulating the relevant enzymes and their specific isoforms having important regulatory roles, it has been of great interest recently to target the energy-related metabolic pathways as part of the therapeutic interventions. OBJECTIVE: This paper summarizes the isozymes overexpressed in breast cancer, their roles of energy metabolism and cross-talks with other important signaling pathways in regulating proliferation, invasion and metastasis in breast cancer. METHOD: Information has been collected from recently published literature available on Google Scholar and PubMed. Where available, in vivo results were given more importance over in vitro works. RESULT: Like many other cancers, breast cancer shows increased dependence on glycolysis rather than mitochondrial respiration, the main energy source in healthy cells. Cancer cells alter the cellular energy system in a way that helps minimize level of reactive oxygen species and simultaneously produce enough macromolecules- proteins, lipids and nucleotides for cellular proliferation. The altered system enables the cells to grow, proliferate, metastasize and to develop drug resistance. Certain isozymes of metabolic enzymes are overexpressed in breast cancer and the degree of expression of these enzymes vary among subtypes. CONCLUSION: A clear understanding of the variations of energy metabolism in different molecular subtypes of breast cancer would help in treating each type with a very customized, safer and efficient treatment regimen. Anti-cancer drugs or RNAi or combination of both targeting cancer cell specific isozymes of metabolic enzymes mentioned in this article could offer a great treatment modality for breast cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Energy Metabolism/drug effects , Animals , Cell Proliferation/drug effects , Female , Humans , Mitochondria/drug effects , Signal Transduction/drug effects
6.
Mol Cancer Ther ; 14(4): 982-93, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25673819

ABSTRACT

The IGFI receptor promotes malignant progression and has been recognized as a target for cancer therapy. Clinical trials with anti-IGFIR antibodies provided evidence of therapeutic efficacy but exposed limitations due in part to effects on, and the compensatory function of, the insulin receptor system. Here, we report on the production, characterization, and biologic activity of a novel, IGF-targeting protein (the IGF-Trap) comprising a soluble form of hIGFIR and the Fc portion of hIgG1. The IGF-Trap has a high affinity for hIGFI and hIGFII but low affinity for insulin, as revealed by surface plasmon resonance. It efficiently blocked IGFIR signaling in several carcinoma cell types and inhibited tumor cell proliferation, migration, and invasion in vitro. In vivo, the IGF-Trap showed favorable pharmacokinetic properties and could suppress the growth of established breast carcinoma tumors when administered therapeutically into tumor-bearing mice, improving disease-free survival. Moreover, IGF-Trap treatment markedly reduced experimental liver metastasis of colon and lung carcinoma cells, increasing tumor cell apoptosis and reducing angiogenesis. Finally, when compared with an anti-IGFIR antibody or IGF-binding protein-1 that were used at similar or higher concentrations, the IGF-Trap showed superior therapeutic efficacy to both inhibitors. Taken together, we have developed a targeted therapeutic molecule with highly potent anticancer effects that could address limitations of current IGFIR-targeting agents.


Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma/metabolism , Carcinoma/pathology , Receptor, IGF Type 1/antagonists & inhibitors , Recombinant Fusion Proteins/pharmacology , Animals , Antibody Specificity , Antineoplastic Agents/chemistry , Antineoplastic Agents/isolation & purification , CHO Cells , Carcinoma/drug therapy , Carcinoma/mortality , Cell Line, Tumor , Cell Proliferation/drug effects , Cricetulus , Disease Models, Animal , Humans , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor II/metabolism , Kinetics , Mice , Neoplasm Metastasis , Protein Binding , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/isolation & purification , Signal Transduction/drug effects , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
8.
Mol Cancer Ther ; 11(7): 1477-87, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22562986

ABSTRACT

Deregulation of TGF-ß superfamily signaling is a causative factor in many diseases. Here we describe a protein engineering strategy for the generation of single-chain bivalent receptor traps for TGF-ß superfamily ligands. Traps were assembled using the intrinsically disordered regions flanking the structured binding domain of each receptor as "native linkers" between two binding domains. This yields traps that are approximately threefold smaller than antibodies and consists entirely of native receptor sequences. Two TGF-ß type II receptor-based, single-chain traps were designed, termed (TßRII)2 and (TßRIIb)2, that have native linker lengths of 35 and 60 amino acids, respectively. Both single-chain traps exhibit a 100 to 1,000 fold higher in vitro ligand binding and neutralization activity compared with the monovalent ectodomain (TßRII-ED), and a similar or slightly better potency than pan-TGF-ß-neutralizing antibody 1D11 or an Fc-fused receptor trap (TßRII-Fc). Despite its short in vivo half-life (<1 hour), which is primarily due to kidney clearance, daily injections of the (TßRII)2 trap reduced the growth of 4T1 tumors in BALB/c mice by 50%, an efficacy that is comparable with 1D11 (dosed thrice weekly). In addition, (TßRII)2 treatment of mice with established 4T1 tumors (100 mm(3)) significantly inhibited further tumor growth, whereas the 1D11 antibody did not. Overall, our results indicate that our rationally designed bivalent, single-chain traps have promising therapeutic potential.


Subject(s)
Protein Engineering , Receptors, Transforming Growth Factor beta/chemistry , Transforming Growth Factor beta/antagonists & inhibitors , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Female , Gene Order , Humans , Immunosuppression Therapy , Ligands , Male , Mice , Mice, Inbred BALB C , Models, Molecular , Protein Binding , Protein Conformation , Protein Stability , Rats , Rats, Sprague-Dawley , Receptors, Transforming Growth Factor beta/genetics , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/pharmacology , Transforming Growth Factor beta/metabolism
9.
J Neurosci ; 25(27): 6263-70, 2005 Jul 06.
Article in English | MEDLINE | ID: mdl-16000615

ABSTRACT

"Fierce" mice, homozygous for the deletion of nuclear receptor 2E1 (NR2E1), show abnormal brain-eye development and pathological aggression. To evaluate functional equivalency between mouse and human NR2E1, we generated mice transgenic for a genomic clone spanning the human NR2E1 locus and bred these animals to fierce mice deleted for the corresponding mouse gene. In fierce mutants carrying human NR2E1, structural brain defects were eliminated and eye abnormalities ameliorated. Excitingly, behavior in these "rescue" mice was indistinguishable from controls. Because no artificial promoter was used to drive transgene expression, promoter and regulatory elements within the human NR2E1 clone are functional in mouse. Normal behavior in rescue animals suggests that mechanisms underlying the behavioral abnormalities in fierce mice may also be conserved in humans. Our data support the hypothesis that variation at NR2E1 may contribute to human behavioral disorders. Use of this rescue paradigm with other genes will permit the direct evaluation of human genes hypothesized to play a causal role in psychiatric disease but for which evidence is lacking or equivocal.


Subject(s)
Aggression/physiology , Brain/abnormalities , Eye Abnormalities/genetics , Receptors, Cytoplasmic and Nuclear/deficiency , Receptors, Cytoplasmic and Nuclear/physiology , Agonistic Behavior/physiology , Animals , Brain/embryology , Cerebral Cortex/abnormalities , Congenital Abnormalities/embryology , Congenital Abnormalities/genetics , Congenital Abnormalities/therapy , Crosses, Genetic , Exploratory Behavior/physiology , Eye Abnormalities/embryology , Eye Abnormalities/therapy , Female , Genotype , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Olfactory Bulb/abnormalities , Orphan Nuclear Receptors , Phenotype , Promoter Regions, Genetic , Receptors, Cytoplasmic and Nuclear/chemistry , Receptors, Cytoplasmic and Nuclear/genetics , Regulatory Sequences, Nucleic Acid , Retina/abnormalities , Reverse Transcriptase Polymerase Chain Reaction , Species Specificity , Territoriality
10.
J Neurosci ; 25(16): 4169-80, 2005 Apr 20.
Article in English | MEDLINE | ID: mdl-15843620

ABSTRACT

Huntington's disease (HD) is an adult-onset neurodegenerative disorder involving motor dysfunction, cognitive deficits, and psychiatric disturbances that result from underlying striatal and cortical dysfunction and neuropathology. The YAC128 mouse model of HD reproduces both the motor deficits and selective degeneration observed in the human disease. However, the presence of cognitive impairment in this model has not been determined. Here, we report mild cognitive deficits in YAC128 mice that precede motor onset and progressively worsen with age. Rotarod testing revealed a motor learning deficit at 2 months of age that progresses such that by 12 months of age, untrained YAC128 mice are unable to learn the rotarod task. Additional support for cognitive dysfunction is evident in a simple swimming test in which YAC128 mice take longer to find the platform than wild-type (WT) controls beginning at 8 months of age. YAC128 mice also have deficits in open-field habituation and in a swimming T-maze test at this age. Strikingly, in the reversal phase of the swimming T-maze test, YAC128 mice take twice as long as WT mice to locate the platform, indicating a difficulty in changing strategy. At 12 months of age, YAC128 mice show decreased prepulse inhibition and habituation to acoustic startle. The clear pattern of cognitive dysfunction in YAC128 mice is similar to the symptoms and progression of cognitive deficits in human HD and provides both the opportunity to examine the relationship between cognitive dysfunction, motor impairment, and neuropathology in HD and to assess whether potential therapies for HD can restore cognitive function.


Subject(s)
Cognition Disorders/etiology , Huntington Disease/pathology , Huntington Disease/physiopathology , Movement Disorders/etiology , Acoustic Stimulation/adverse effects , Age Factors , Analysis of Variance , Animals , Behavior, Animal , Disease Models, Animal , Dose-Response Relationship, Radiation , Exploratory Behavior/physiology , Habituation, Psychophysiologic , Huntington Disease/genetics , Inhibition, Psychological , Maze Learning/physiology , Memory/physiology , Mice , Motor Activity/genetics , Motor Activity/physiology , Psychomotor Performance/physiology , Reflex, Acoustic/physiology , Rotarod Performance Test/methods , Swimming/physiology , Time Factors
11.
Hum Mol Genet ; 12(13): 1555-67, 2003 Jul 01.
Article in English | MEDLINE | ID: mdl-12812983

ABSTRACT

An expanded CAG repeat is the underlying genetic defect in Huntington disease, a disorder characterized by motor, psychiatric and cognitive deficits and striatal atrophy associated with neuronal loss. An accurate animal model of this disease is crucial for elucidation of the underlying natural history of the illness and also for testing experimental therapeutics. We established a new yeast artificial chromosome (YAC) mouse model of HD with the entire human HD gene containing 128 CAG repeats (YAC128) which develops motor abnormalities and age-dependent brain atrophy including cortical and striatal atrophy associated with striatal neuronal loss. YAC128 mice exhibit initial hyperactivity, followed by the onset of a motor deficit and finally hypokinesis. The motor deficit in the YAC128 mice is highly correlated with striatal neuronal loss, providing a structural correlate for the behavioral changes. The natural history of HD-related changes in the YAC128 mice has been defined, demonstrating the presence of huntingtin inclusions after the onset of behavior and neuropathological changes. The HD-related phenotypes of the YAC128 mice show phenotypic uniformity with low inter-animal variability present, which together with the age-dependent striatal neurodegeneration make it an ideal mouse model for the assessment of neuroprotective and other therapeutic interventions.


Subject(s)
Huntington Disease/metabolism , Huntington Disease/pathology , Nerve Tissue Proteins/genetics , Neurons/metabolism , Nuclear Proteins/genetics , Age Factors , Animals , Blotting, Southern , Brain/pathology , Brain/ultrastructure , Chromosomes, Artificial, Yeast , Disease Models, Animal , Humans , Huntingtin Protein , Huntington Disease/genetics , Mice , Microscopy, Electron , Mutagenesis , Neurons/pathology , Phenotype , RNA/metabolism , Time Factors , Trinucleotide Repeats
SELECTION OF CITATIONS
SEARCH DETAIL
...